Question-and-Answer Session
Operator
Thank you. (Operator Instructions) Our first question comes from the line of Aaron Mishel with Thomas Weisel Partners.
Aaron Mishel - Thomas Weisel Partners
Hi. Congratulations on the quarter.
Martha Hough
Thank you.
Aaron Mishel - Thomas Weisel Partners
Few questions here. D you have any price increases on ZEGERID in the quarter?
Bill Denby
We took a price increase on ZEGERID in January.
Aaron Mishel - Thomas Weisel Partners
And what percent was that?
Bill Denby
Its 9% on the capsule.
Gerry Proeh
Capsule and a little bit less on our?
Aaron Mishel - Thomas Weisel Partners
Okay. And then on the promotion revenues. I noticed a sequential -- quarterly sequential decline. Was there something in there beside GLUMETZA last quarter or kind of how you explain the sequential decline?
Debbie Crawford
Yeah this is Debbie. We had mentioned that when you think about the promotion revenue, it really is tied to the net sales and then the gross margin of the GLUMETZA products and that's based upon Depomed’s sales of the product.
So what we had seen in the fourth quarter was generally perhaps a little bit of stocking in the channel associated with the launch of the 1,000 milligram tablet form and so in the first quarter as we had anticipated, what you saw was a little bit of leveling off where the prescriptions were closer to the actual shipments of the products, whereas in the fourth quarter we believe there has been a little bit of inventory holding with the channel, given the launch activity.
Aaron Mishel - Thomas Weisel Partners
Okay, that’s helpful. And then on research and development expense, I mean, we have guidance for the full year, can you give us any color on how you see that cost being allocated over the remaining three quarters?
Debbie Crawford
I appreciate that question Aaron but really at this time, I think all we can provide you with is a test for our payment for instance, putting resources behind our development programs and that we would expect to see R&D expenses increasing, most likely sequentially as we move through the year.
It really is a factor of enrollment activity on the Phase III trial as well as other development activities. But we do want to give investors some visibility to the fact that we do expect basically that increasing as we move through the year.
- To read the full transcript on Seeking Alpha, click here »
